treatment

Biomarker testing informs individualized diagnosis and treatment of low-to-intermediate risk AML

Biomarker testing informs individualized diagnosis and treatment of low-to-intermediate risk AML

Alexander E. Perl, MD, MS. According to Alexander E. Perl, MD, MS, the acute myeloid leukemia (AML) treatment landscape includes emerging therapies and diagnostic strategies that simultaneously address previously unmet needs and raise further questions regarding the classification of diseases. In 2022, the European LeukemiaNet (ELN) updated its AML recommendations based on a growing understanding …

Biomarker testing informs individualized diagnosis and treatment of low-to-intermediate risk AML Read More »

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment

A featured discussion sheds light on how the Combined Risk Score can lead to better breast cancer prevention and screening strategies. SALT LAKE CITY, Nov. 29, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new data presentations at the San Antonio Breast Cancer …

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium, Showcasing Advances in Breast Cancer Risk Assessment and Treatment Read More »